News - 24 Oct 2023

Q3 2023: New strategic focus and improved sales trend

Important events during the third quarter

  • Net sales increased by 8% (6% adjusted for currency effects) to SEK 156 m (145).
  • The EBITDA margin amounted to 18% (25) or 20% adjusted for items affecting comparability.
  • New strategic focus areas and financial targets.
  • New clinical study in metabolic health shows clear benefits with Probi's bacterial strains, which opens up a new health area.
  • Third clinical trial of HEAL9™ published, strengthens evidence of improved cognitive performance.

Read the entire report here.